ADALIMUMAB

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes

ADALIMUMAB (15020M)

adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes
15020M
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 1 treatment (Whole body) - biological medicine-naive patient

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 2 treatment (Whole body) - Change of treatment, or, recommencement of treatment after a break in biological medicine of less than 5 years

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 3 treatment (Whole body, or, face/hand/foot) - Recommencement of treatment after a break in biological medicine of more than 5 years

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Balance of supply - Initial 1, 2 or 3 treatment (Whole body, or, face/hand/foot)

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 1 treatment (Face, hand, foot) - biological medicine-naive patient

Restriction

Indication: Severe chronic plaque psoriasis
Treatment phase: Initial 2 treatment (Face, hand, foot) - Change of treatment, or, recommencement of treatment after a break in biological medicine of less than 5 years
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 4 DPMQ: $494.12 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Amgevita
Hadlima
Hyrimoz